This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Labcorp Q4 Earnings & Revenues Beat, Margins Down, Stock Tumbles
by Zacks Equity Research
LH delivers better-than-expected revenues and earnings in the fourth quarter of 2024.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Hologic Q1 Earnings Beat, Stock Falls on Dismal '25 Sales Guidance
by Zacks Equity Research
HOLX's fiscal 2025 first-quarter results reflect the strength of its Molecular Diagnostics business.
MCK Stock Down on Q3 Earnings & Sales Miss, Gross Margin Contracts
by Zacks Equity Research
McKesson's third-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket
by Zacks Equity Research
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment.
McKesson Stock May Rise With PRISM Vision Holdings Acquisition
by Zacks Equity Research
MCK is set to acquire a controlling stake in PRISM Vision Holdings, aiming to expand its specialty care capabilities and strengthen its leadership in eye health solutions across the United States.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its robust product portfolio and strong segmental performance.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BSX Q4 Earnings & Revenues Top, Stock Falls on Weak Gross Margin
by Zacks Equity Research
Boston Scientific's fourth-quarter 2024 performance reflects the strength of its core franchises.
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
by Zacks Equity Research
NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.
GEHC Stock May Rise With $138M Investment in Cork Facility Expansion
by Zacks Equity Research
GE HealthCare invests $138M to expand its Cork facility to enhance manufacturing capacity for life-saving imaging contrast media and strengthen its global supply chain.
IDEXX Q4 Earnings and Revenues Top Estimates, Stock Up in Pre-Market
by Zacks Equity Research
IDXX delivers better-than-expected earnings and revenues in the fourth quarter of 2024.
ResMed Q2 Earnings and Revenues Beat, Stock Up in Pre-Market
by Zacks Equity Research
RMD's stellar second-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
ANGO Stock Looks Promising on New Ischemia Study for Auryon System
by Zacks Equity Research
AngioDynamics initiates the AMBITION BTK RCT and registry to advance treatment for patients with chronic limb-threatening ischemia and below-the-knee peripheral artery disease.
Thermo Fisher Q4 Earnings and Revenues Top Estimates, Stock Up
by Zacks Equity Research
In the fourth quarter of 2024, TMO continued to advance its growth strategy and trusted partner status with customers.
CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised
by Zacks Equity Research
Cardinal Health's second-quarter fiscal 2025 results benefit from solid Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL continues to witness growth on the back of its strong product portfolio.
Here's Why Cardinal Health (CAH) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cardinal (CAH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Wall Street Analysts Think Cardinal (CAH) Is a Good Investment: Is It?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Cardinal (CAH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Cardinal Health (CAH) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 10.29% and 0.69%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Stryker Stock Falls on Deal to Sell Its U.S. Spinal Implants Business
by Zacks Equity Research
SYK announces agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC.
Why Cardinal Health (CAH) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Merit Medical Systems, Inc. (MMSI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Inogen Stock May Gain on Deal With Yuwell to Expand Global Reach
by Zacks Equity Research
INGN and Yuwell collaborate to expand and enhance Inogen's innovation pipeline through R&D collaboration and accelerate the entry of Inogen's brand into the Chinese market.